GSK PLC-SPON ADR (GSK) Stock Institutional Trading Activity


GSK PLC-SPON ADR (GSK) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q4 2025), investors with some of the largest reported share count changes include Causeway Capital Management, Renaissance Technologies LLC, Kahn Brothers Group, Hancock Classic Value, and Dodge & Cox Stock Fund. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.

Explore more:

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q4 2024Dodge & Cox Stock FundBuy353,74968,440,912$2,314,671,644
Q4 2024Tweedy, Browne Co All Funds (US)Sell-14,21993,816$3,172,857
Q3 2024Sequoia Financial AdvisorsBuy57722,937$937,665
Q3 2024Hillman Value FundBuy1,770196,896$8,049,108
Q3 2024Causeway Capital ManagementBuy143,871897,406$36,685,942
Q3 2024Renaissance Technologies LLCSell-12,5002,335,493$95,474,954
Q3 2024Dodge & Cox Stock FundSell-249,97568,087,163$2,783,403,223
Q3 2024Tweedy, Browne Co All Funds (US)Sell-1,820108,035$4,416,471
Q2 2024Sequoia Financial AdvisorsBuy18322,360$860,854
Q2 2024Hillman Value FundSell-38,360195,126$7,512,336
Q2 2024Causeway Capital ManagementBuy16,350753,535$29,011,113
Q2 2024Renaissance Technologies LLCBuy554,6002,347,993$90,397,731
Q2 2024Dodge & Cox Stock FundSell-525,17068,337,138$2,630,979,813
Q2 2024Tweedy, Browne Co All Funds (US)Sell-13,189109,855$4,229,418
Q1 2024Renaissance Technologies LLCSell-971,8001,793,393$76,883
Q1 2024Sequoia Financial AdvisorsBuy1,00022,177$950,728
Q1 2024Hillman Value FundBuy100233,486$10,009,545
Q1 2024Causeway Capital ManagementSell-58,256737,185$31,603,132
Q1 2024Dodge & Cox Stock FundSell-164,48568,862,308$2,952,127,144
Q1 2024Tweedy, Browne Co All Funds (US)Sell-1,356123,044$5,274,896
Q4 2023Renaissance Technologies LLCSell-146,8002,765,193$102,478
Q4 2023Sequoia Financial AdvisorsBuy5,48521,177$784,912
Q4 2023Ariel Appreciation FundSell-86,10555,392$2,052,828
Q4 2023Hillman Value FundBuy522233,386$8,649,285
Q4 2023Causeway Capital ManagementBuy230,694795,441$29,479,046
Q4 2023Dodge & Cox Stock FundSell-254,39069,026,793$2,558,132,949
Q4 2023Tweedy, Browne Co All Funds (US)Sell-5,594124,400$4,610,264
Q3 2023Renaissance Technologies LLCSell-110,1412,911,993$105,560
Q3 2023Sequoia Financial AdvisorsBuy1,58515,692$568,930
Q3 2023Ariel Appreciation FundSell-30,180141,497$5,129,266

Frequently asked questions about GSK activity

  • Which institutional owners are buying GSK?

    Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in GSK activity?

    "Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in GSK increasing?

    Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.